Ethoxzolamide

Ethoxzolamide Overview

Ethoxzolamide (chemically designated as 6-ethoxy-1,3-benzothiazole-2-sulfonamide; chemical formula C9H10N2O3S2) is a synthetic substituted benzothiazole sulfonamide derivative. Chemically, it belongs to the class of organic compounds known as benzothiazoles within the organoheterocyclic superclass. Structurally, it consists of a fused benzene and thiazole ring system substituted with a 6-ethoxy ether group and a 2-sulfonamide moiety.

In neurology, ophthalmology, and renal pharmacology, Ethoxzolamide functions as a potent carbonic anhydrase inhibitor, diuretic, and anticonvulsant agent (ATC code G01AE10 for sulfonamide combinations). Formulated as oral tablets (marketed under former trade names such as Cardrase and Ethamide), it was indicated for reducing intraocular pressure in open-angle glaucoma, promoting diuresis in fluid retention, adjunctive management of absence and tonic-clonic seizures in epilepsy, and reducing gastric acid secretion in peptic ulcer disease. By blocking carbonic anhydrase isoenzymes across various tissues, it inhibits bicarbonate reabsorption and fluid secretion. Although approved historically by the US FDA, commercial distribution of Ethoxzolamide has been discontinued.

What Is Ethoxzolamide and How Does It Work?

Ethoxzolamide acts primarily through reversible inhibition of carbonic anhydrase isoenzymes (CA-I, CA-II, CA-IV, and CA-VII), suppressing bicarbonate, sodium, and water transport across epithelial and central nervous system membranes.

Its primary chemical, physiological, and pharmacological mechanisms include:

• Enzymatic Carbonic Anhydrase Inhibition: Ethoxzolamide binds with high affinity to the catalytic zinc site of carbonic anhydrase enzymes (particularly CA-I, CA-II, CA-IV, and CA-VII), blocking the reversible hydration of carbon dioxide (CO2​+H2​O⇌H2​CO3​⇌HCO3−​+H+).
• Renal Tubular Diuresis: In the proximal renal tubules, inhibition of CA-II and CA-IV reduces hydrogen ion (H+) availability for sodium-hydrogen exchange. This decreases renal tubular reabsorption of bicarbonate, sodium, potassium, and water, leading to alkaline diuresis and mild metabolic acidosis.
• Ocular Intraocular Pressure Reduction: In the ciliary body of the eye, CA inhibition decreases bicarbonate secretion into aqueous humor, reducing fluid formation and lowering intraocular pressure in glaucoma.
• Central Nervous System Seizure Suppression: In the central nervous system, CA inhibition leads to local metabolic acidosis, alters neuronal membrane carbon dioxide gradient dynamics, and elevates brain GABA levels, dampening abnormal, excessive neuronal discharge in epilepsy.
• Gastric Acid Secretion Reduction: By blocking carbonic anhydrase in gastric mucosal parietal cells, it decreases the generation of hydrogen ions required for hydrochloric acid secretion, aiding ulcer healing.

Is Ethoxzolamide FDA Approved?

Ethoxzolamide was approved by the US FDA under trade names such as Ethamide and Cardrase. Production and commercial marketing were subsequently discontinued. Its current approval status is FDA Approved (January 1982); Discontinued (January 1982).

What Was Ethoxzolamide Used For?

• Reduction of elevated intraocular pressure in primary open-angle glaucoma and secondary glaucoma.
• Adjunctive treatment of seizures, including absence (petit mal) and tonic-clonic (grand mal) epilepsy.
• Diuretic therapy for fluid retention associated with congestive heart failure or edema.
• Historical treatment of duodenal and peptic ulcers by suppressing gastric acid secretion.

Before Taking Ethoxzolamide: Contraindications & Precautions

Do not administer Ethoxzolamide to patients with a history of severe sulfonamide hypersensitivity. Avoid in patients with severe hepatic impairment, liver cirrhosis, severe renal disease, hyperchloremic acidosis, baseline hypokalemia, hyponatremia, or Addison’s disease.

Who Should Not Take Ethoxzolamide?

• Individuals with known severe hypersensitivity to Ethoxzolamide, thiazides, or other sulfonamide-derived medications.
• Patients with severe renal insufficiency, acute renal failure, or anuria.
• Patients with severe liver dysfunction, hepatic encephalopathy, or biliary cirrhosis.
• Individuals with uncorrected hypokalemia, hyponatremia, hyperchloremic metabolic acidosis, or adrenal gland insufficiency (Addison’s disease).

Ethoxzolamide, Pregnancy & Safety

Preclinical animal studies involving high-dose carbonic anhydrase inhibitors demonstrate teratogenic potential, including limb reduction defects and axial skeletal malformations. Well-controlled clinical safety studies in human pregnancy are lacking. Ethoxzolamide should not be used during pregnancy unless potential therapeutic benefits clearly outweigh fetal risks. Trace amounts may be excreted in human breast milk; caution is advised during lactation.

Tell Your Doctor Before Taking Ethoxzolamide

Inform your physician or neurologist if you have a history of sulfonamide allergy, kidney stones, chronic obstructive pulmonary disease (COPD), diabetes mellitus, gout, or electrolyte imbalances.

Ethoxzolamide Dosage & Administration

Formulated historically as oral tablets containing 62.5 mg or 125 mg of Ethoxzolamide.

Standard Ethoxzolamide Dosing

• Glaucoma Dosing (Adults): Administered historically as 62.5 mg to 125 mg orally two to four times daily based on intraocular pressure readings.
• Epilepsy Dosing (Adults): Administered as 125 mg to 250 mg orally two to three times daily as an adjunct to primary anticonvulsant therapy.
• Diuretic Dosing (Adults): Administered as 62.5 mg to 125 mg orally once daily or on alternate days to reduce fluid retention.

How Ethoxzolamide Was Administered

• Administered orally with a full glass of water, preferably with food or milk to minimize gastrointestinal irritation.
• Doses were spaced evenly throughout the day for continuous intraocular or central nervous system effect.

Ethoxzolamide Clinical Efficacy & Safety Profile

In historical clinical practice, Ethoxzolamide served as an effective oral carbonic anhydrase inhibitor capable of producing rapid drops in intraocular pressure and promoting alkaline diuresis. However, like other systemic carbonic anhydrase inhibitors (such as acetazolamide), its long-term clinical utility was limited by systematic adverse effects, including systemic metabolic acidosis, severe hypokalemia, fatigue, paresthesias, and renal calculus formation. In modern medicine, systemic oral carbonic anhydrase inhibitors have largely been superseded by topical ocular carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide) for glaucoma, and newer antiepileptic drugs for seizure management.

Ethoxzolamide Side Effects & Safety Profile

Common adverse effects include paresthesias (tingling in fingers and toes), fatigue, drowsiness, loss of appetite, nausea, vomiting, polyuria, and altered taste (dysgeusia). Serious adverse risks include severe hypokalemia, metabolic acidosis, bone marrow suppression (aplastic anemia, agranulocytosis), Stevens-Johnson syndrome, and nephrolithiasis. Holds no FDA Black Box Warning.

Common Ethoxzolamide Side Effects

• Neurological & Sensory: Numbness or tingling sensation in the hands, feet, or lips (paresthesia), fatigue, drowsiness, dizziness, and metallic taste.
• Gastrointestinal & Metabolic: Loss of appetite (anorexia), nausea, vomiting, abdominal cramps, increased urination (polyuria), and weight loss.

Serious Ethoxzolamide Adverse Events

• Electrolyte Imbalances & Acidosis: Severe hypokalemia, hyponatremia, and hyperchloremic metabolic acidosis.
• Sulfonamide Hypersensitivity & Dermatological: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and severe allergic dermatitis.
• Hematological Toxicity: Severe bone marrow depression, including aplastic anemia, agranulocytosis, leukopenia, and thrombocytopenia.
• Renal Calculus Formation: Precipitation of calcium phosphate kidney stones (nephrolithiasis) due to persistent urinary alkalinization.

Managing Ethoxzolamide Side Effects

Monitor serum electrolytes (potassium, sodium, bicarbonate) and blood counts regularly. Treat hypokalemia with oral potassium supplementation or dietary adjustment. Discontinue therapy immediately if severe skin rash or blood dyscrasias occur.

Ethoxzolamide Drug Interactions & What to Avoid

Co-administration with high-dose salicylates, diuretics, or cardiac glycosides increases systemic toxicity risks.

Ethoxzolamide Drug-Drug Interactions

• High-Dose Salicylates (e.g., Aspirin): Carbonic anhydrase inhibition alters plasma pH, increasing brain penetration of salicylates and causing severe central nervous system toxicity and metabolic acidosis.
• Digitalis Glycosides (e.g., Digoxin): Ethoxzolamide-induced hypokalemia significantly increases the risk of digitalis-induced cardiac arrhythmias.
• Other Diuretics (e.g., Furosemide, Hydrochlorothiazide): Additive electrolyte loss increases the risk of severe hypokalemia and dehydration.
• Lithium: Increased renal elimination of lithium may lower serum lithium concentrations and reduce therapeutic efficacy.

Ethoxzolamide, Food & Alcohol

Maintain adequate fluid intake to reduce the risk of kidney stone formation. Avoid alcohol consumption, as alcohol can worsen central nervous system depression and dizziness.

Ethoxzolamide: Missed Dose, Overdose & Storage

Historical administration was on a fixed daily schedule. Overdose produces severe electrolyte loss and metabolic acidosis. Store at room temperature (15°C–25°C).

Missed Dose of Ethoxzolamide

Take the missed dose as soon as remembered. If it is nearly time for your next scheduled dose, skip the missed dose and resume your normal dosing schedule. Do not double doses.

Ethoxzolamide Overdose & Emergency

Acute overdose causes severe electrolyte imbalance, marked hyperchloremic metabolic acidosis, extreme fatigue, drowsiness, confusion, paresthesias, nausea, and dehydration. Emergency management involves gastric lavage, intravenous isotonic saline and potassium supplementation, alkali therapy (sodium bicarbonate) to correct acidosis, and supportive care.

How to Store Ethoxzolamide

Store tablets at controlled room temperature between 15°C and 25°C (59°F to 77°F). Protect from light and moisture. Keep containers tightly closed and strictly out of reach of children.

Ethoxzolamide Patient Management & Monitoring

Requires routine monitoring of serum electrolytes, renal function, intraocular pressure, and complete blood counts.

Tests Before Starting Ethoxzolamide

Baseline serum electrolytes (potassium, sodium, chloride, bicarbonate), blood urea nitrogen (BUN), serum creatinine, complete blood count (CBC) with differential, and baseline intraocular pressure measurement.

Monitoring During Ethoxzolamide Treatment

Periodic serum electrolyte and blood pH testing; monitoring CBC for signs of blood dyscrasias; tracking intraocular pressure in glaucoma patients; monitoring for signs of kidney stones.

Ethoxzolamide Do’s and Don’ts

• Do drink plenty of fluids daily to reduce the risk of kidney stones.
• Do report persistent tingling, extreme fatigue, sore throat, or skin rash to your doctor immediately.
• Do not take high-dose aspirin while taking Ethoxzolamide without medical guidance.
• Do not drive or operate machinery if you experience drowsiness or dizziness.

Frequently Asked Questions

References

• DrugBank Database – Ethoxzolamide Clinical Profile (DB00311)
• Classyfire Database – Benzothiazoles / Organoheterocyclic Compounds Taxonomy Profile
• US Food and Drug Administration (FDA) Drug Approvals and Discontinuations Database

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.